Avid Bioservices, Inc. (CDMO): Price and Financial Metrics

Avid Bioservices, Inc. (CDMO): $18.00

0.05 (+0.28%)

POWR Rating

Component Grades














  • CDMO scores best on the Sentiment dimension, with a Sentiment rank ahead of 68.49% of US stocks.
  • CDMO's strongest trending metric is Stability; it's been moving up over the last 178 days.
  • CDMO's current lowest rank is in the Quality metric (where it is better than 6.49% of US stocks).

CDMO Stock Summary

  • Of note is the ratio of AVID BIOSERVICES INC's sales and general administrative expense to its total operating expenses; 87.09% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for AVID BIOSERVICES INC is higher than it is for about 86.91% of US stocks.
  • With a price/sales ratio of 7.91, AVID BIOSERVICES INC has a higher such ratio than 85.95% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to AVID BIOSERVICES INC, a group of peers worth examining would be SGBX, WORX, JUPW, LEN, and CDAY.
  • CDMO's SEC filings can be seen here. And to visit AVID BIOSERVICES INC's official web site, go to avidbio.com.

CDMO Valuation Summary

  • CDMO's price/sales ratio is 7.9; this is 315.79% higher than that of the median Healthcare stock.
  • CDMO's EV/EBIT ratio has moved up 275.8 over the prior 243 months.

Below are key valuation metrics over time for CDMO.

Stock Date P/S P/B P/E EV/EBIT
CDMO 2023-03-17 7.9 6.0 9.6 271.9
CDMO 2023-03-16 8.1 6.1 9.8 277.3
CDMO 2023-03-15 7.8 5.9 9.4 267.3
CDMO 2023-03-14 8.4 6.3 10.1 285.5
CDMO 2023-03-13 6.1 4.7 7.4 217.0
CDMO 2023-03-10 6.5 4.8 7.4 223.4

CDMO Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 181.63%.
  • Its 3 year revenue growth rate is now at 123.12%.
  • The 3 year price growth rate now stands at 279.25%.
Over the past 15 months, CDMO's revenue has gone up $32,953,000.

The table below shows CDMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 134.183 -2.967 118.254
2022-06-30 125.535 11.373 122.932
2022-03-31 119.597 9.465 127.672
2021-12-31 115.977 26.713 9.775
2021-09-30 106.275 26.71 8.292
2021-06-30 101.23 26.513 5.612

CDMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDMO has a Quality Grade of C, ranking ahead of 27.37% of graded US stocks.
  • CDMO's asset turnover comes in at 0.495 -- ranking 83rd of 682 Pharmaceutical Products stocks.
  • COCP, HROW, and IBIO are the stocks whose asset turnover ratios are most correlated with CDMO.

The table below shows CDMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 0.495 0.318 0.126
2021-04-30 0.587 0.306 0.157
2021-01-31 0.653 0.246 0.079
2020-10-31 0.672 0.199 0.002
2020-07-31 0.659 0.163 -0.044
2020-04-30 0.568 0.066 -0.173

CDMO Price Target

For more insight on analysts targets of CDMO, see our CDMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.25 Average Broker Recommendation 1.38 (Strong Buy)

CDMO Stock Price Chart Interactive Chart >

Price chart for CDMO

CDMO Price/Volume Stats

Current price $18.00 52-week high $22.38
Prev. close $17.95 52-week low $11.30
Day low $17.95 Volume 502,200
Day high $18.38 Avg. volume 609,778
50-day MA $16.36 Dividend yield N/A
200-day MA $16.36 Market Cap 1.13B

Avid Bioservices, Inc. (CDMO) Company Bio

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate includes bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company was founded in 1981 and is based in Tustin, California.

CDMO Latest News Stream

Event/Time News Detail
Loading, please wait...

CDMO Latest Social Stream

Loading social stream, please wait...

View Full CDMO Social Stream

Latest CDMO News From Around the Web

Below are the latest news stories about AVID BIOSERVICES INC that investors may wish to consider to help them evaluate CDMO as an investment opportunity.

Dow Extends Rebound, Surges 456 Points

Rallying bank stocks are fueling Wall Street's midday gains, as investors continue to unpack this morning's consumer price index (CPI) data.

TalkMarkets.com | March 14, 2023

Why Avid Bioservices Stock Is Surging Today

Shares of the contract development and manufacturing organization Avid Bioservices (NASDAQ: CDMO) were up by a healthy 34% on heavy volume as of 11 a.m. ET Tuesday. After this double-digit move higher, the bio-manufacturing company's stock is now trading at 6.5 times 2024 estimated sales.

Yahoo | March 14, 2023

Avid Bioservices, Inc. (NASDAQ:CDMO) Q3 2023 Earnings Call Transcript

Avid Bioservices, Inc. (NASDAQ:CDMO) Q3 2023 Earnings Call Transcript March 13, 2023 Operator: Good day, ladies and gentlemen and welcome to the Avid Bioservices Third Quarter Fiscal 2023 Financial Results Conference Call. As a reminder, this conference call maybe recorded. I would now like to hand the conference over to Tim Brons of Avid’s Investor […]

Yahoo | March 14, 2023

Declining Stock and Solid Fundamentals: Is The Market Wrong About Avid Bioservices, Inc. (NASDAQ:CDMO)?

Avid Bioservices (NASDAQ:CDMO) has had a rough month with its share price down 16%. However, a closer look at its sound...

Yahoo | March 14, 2023

Q3 2023 Avid Bioservices Inc Earnings Call

Q3 2023 Avid Bioservices Inc Earnings Call

Yahoo | March 14, 2023

Read More 'CDMO' Stories Here

CDMO Price Returns

1-mo N/A
3-mo 28.30%
6-mo 0.28%
1-year -18.40%
3-year 471.43%
5-year 617.13%
YTD 30.72%
2022 -52.81%
2021 152.86%
2020 50.46%
2019 87.07%
2018 5.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8443 seconds.